Immucell (ICCC) Non Operating Interest Expenses (2012 - 2026)
Immucell's (ICCC) quarterly Non Operating Interest Expenses came in at $95667.0 in Q2 2026, down 23.34% on a YoY basis from $124795.0 in Q2 2025, and down 9.87% quarter-over-quarter from $106145.0 in Q4 2025.
Powered by 
Analysis
Immucell (ICCC) Non Operating Interest Expenses (2012 - 2026) Analysis & Trends
Immucell (ICCC) has reported Non Operating Interest Expenses for 13 consecutive years, with $95667.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Interest Expenses fell 23.34% year-over-year to $95667.0; the trailing twelve-month figure through Jun 2026 stood at $461123.0 (down 15.78% YoY), and the FY2025 full-year result was $493384.0, down 13.25% from the prior year.
- Non Operating Interest Expenses retreated to $95667.0 in Q2 2026 per ICCC's latest filing, from $106145.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $146003.0 in Q1 2024 and bottomed at $88577.0 in Q2 2023.
- Historically, Non Operating Interest Expenses has averaged $120841.0 across 4 years, with a median of $129655.5 in 2025.
- The sharpest annual moves came in 2024 and 2026: Non Operating Interest Expenses soared 62.25% in 2024, then dropped 23.34% in 2026.
- Over 4 years, Non Operating Interest Expenses stood at $88577.0 in 2023, then surged by 53.76% to $136196.0 in 2024, then declined by 22.06% to $106145.0 in 2025, then decreased by 9.87% to $95667.0 in 2026.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $95667.0, $106145.0, and $134516.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn | 10.18 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn | - |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | - |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn | 10.71 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn | 95,667.00 |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 95,667.00 |
| Dec 31, 2025 | 106,145.00 |
| Sep 30, 2025 | 134,516.00 |
| Jun 30, 2025 | 124,795.00 |
| Dec 31, 2024 | 136,196.00 |
| Sep 30, 2024 | 144,141.00 |
| Jun 30, 2024 | 142,386.00 |
| Mar 31, 2024 | 146,003.00 |
| Jun 30, 2023 | 88,577.00 |
| Mar 31, 2023 | 89,984.00 |
| Sep 30, 2020 | 71,290.00 |
| Jun 30, 2020 | 74,524.00 |
| Mar 31, 2020 | 333,776.00 |
| Dec 31, 2019 | 71,608.00 |
| Sep 30, 2019 | 65,280.00 |
| Jun 30, 2019 | 64,891.00 |
| Mar 31, 2019 | 111,726.00 |
| Dec 31, 2018 | 111,817.00 |
| Sep 30, 2018 | 106,414.00 |
| Jun 30, 2018 | 103,134.00 |